hiv-1 inhibitor-3

HIV-1 inhibitor-3 is an HIV infection inhibitor.

HIV-1 integrase inhibitor 3 is an HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 2.7 nM.

HIV-1 inhibitor-36 (Compound 2) is a potent HIV-1 inhibitor with significant potential as a novel latency-reversing agent [1].

HIV-1 inhibitor-37 (Compound 83) is a potent HIV-1 inhibitor with significant potential as an innovative latent HIV-1 reactivating agent [1].

HIV-1 inhibitor-30 (compound 10i) is a potent inhibitor of HIV-1, specifically targeting the RT DNA polymerase enzyme, showing strong antiretroviral activity with an EC50 value of 40 nM and an IC50 value of 80 nM. Moreover, it demonstrates significant effectiveness against seven NNRTI-resistant strains of HIV-1 (RT-K103N; RT-Y181C; RT-K103N, Y181C; RT-L100I, K103N; RT-Y188L; RT-K103N, G190A; RT-K103N, V108I), with IC50 values from 0.04 to 1.42 μM. This compound holds potential for AIDS research [1].

HIV-1 inhibitor-38 (Compound 91) is a potent HIV-1 activity inhibitor and shows significant potential as a novel latency reversing agent, making it a promising candidate for further development [1].

HIV-1 inhibitor-35 (compound 74) is a highly potent inhibitor of the HIV-1 virus, exhibiting EC50 values of 80 nM and 70 nM for LTR and CMV, respectively, in HEK293 cells. Additionally, it demonstrates inhibitory activity against HepG2 liver cancer cells, with a CC50 value of 40 nM, and shows promise as a potential HIV-1 latency reversing agent [1].

HIV-1 inhibitor-31 (compound 4) is a potent inhibitor of HIV-1 and can be used in the study of AIDS.

HIV-1 inhibitor-33 (compound 5n) is a potent and selective HIV-1 inhibitor with an EC50 of 8.6 nM and a CC50 of 18 μM in MT-4 cells, and can be used in the study of AIDS.

HIV-1 inhibitor-34 (compound 5q) is a potent and selective HIV-1 inhibitor, with an EC50 of 6.4 nM for HIV-1 and a CC50 of 16 μM in MT-4 cells, making it useful for AIDS research.

HIV-1 inhibitor-32 is a potent inhibitor of HIV-1 that acts on wild-type HIV (IC50: 34 nM) and can be used in AIDS research.

HIV-1 inhibitor-39 is a potent inhibitor of HIV-1 (EC50>112.88 μM). HIV-1 inhibitor-39 has anti-RT (HIV-1 reverse transcriptase) effect (IC50: 15.75 μM). HIV-1 inhibitor-39 exhibits cytotoxicity against MT-4 cells (CC50: 112.9 μM).

Apricitabine (SPD754) is a highly selective and orally active HIV-1 reverse transcriptase inhibitor (Ki=0.08 μM), the (-) enantiomer of 2′-deoxy-3′-oxy-4′-thiocytidine (dOTC) . Apricitabine inhibits DNA polymerase α, β and γ with Ki values of 300 μM, 12 μM and 112.25 μM, respectively. Apricitabine has shown good antiretroviral therapeutic efficacy in antiretroviral HIV-infected patients, with good tolerability and low selective resistance.

PDDC inhibitor (Phenyl (R)-(1-(3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-yl)pyrrolidin-3-yl)carbamate) is a selective and highly potent nSMase2 inhibitor.

Gamibetal (4-Amino-3-hydroxybutyric Acid) is used as a chiral reagent in the synthesis of antiepileptic and hypotensive drug GABOB and analogues. Also used in the preparation of HIV-1 inhibitors derived from Betulinic Acid (B330250).

Lamivudine (BCH-189) is a reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.

Dolutegravir intermediate-1 (1-(2,2-dimethoxyethyl)-5-methoxy-6-(methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid) is a new synthetic Dolutegravir intermediate. Dolutegravir is an integrase inhibitor developed for the treatment of human immunodeficiency virus (HIV)-1 infection.

Q-VD-OPH (Quinoline-Val-Asp-Difluorophenoxymethylketone) is a pan-caspase inhibitor with potent antiapoptotic properties.

Lenacapavir (GS-6207) is the first HIV-1 capsid inhibitor approved by the U.S. Food and Drug Administration, the European Medicines Agency, and Health Canada for the treatment of MDR HIV-1 infection.[3]

Tizoxanide (Desacetyl-nitazoxanide) is a metabolite of lamivudine. Lamivudine (2', 3'-dideoxy-3'-thiacytidine, commonly called 3TC) is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).

3'-Azido-3'-deoxy-5-methylcytidine inhibits HIV-1 reverse transcriptase (EC50 = 0.06 μM) and is an effective inhibitor of xenotropic murine leukemia-related retrovirus [XMRV, CC50 = 43.5 μM].

beta-L-D4A, a nucleoside HIV-1 reverse transcriptase inhibitor, exhibits biological activity by terminating DNA chain synthesis in the 5'-3' direction.

3-Deazaadenosine hydrochloride is an inhibitor of S-adenosylhomocysteine hydrolase (Ki: 3.9 µM). It has anti-inflammatory, anti-proliferative, and anti-HIV activity.

BRD-6929 is a selective, brain-penetrant HDAC1 and HDAC2 inhibitor (IC50:  1 and 8 nM). BRD-6929 (Cpd-60) shows high-affinity to HDAC1 and HDAC2 (Kis: 0.2 and 1.5 nM) [2]. BRD-6929 potentiates the efficacy of gnidimacrin (a PKC Agonist) against latent HIV